ArticleJournal of Alzheimer's disease reports
N-Glycosylation and Alzheimer's disease: A 2001-2025 global bibliometric landscape revealing emerging diagnostic trends.
Article in Journal of Alzheimer's disease reports. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Protein Modifications and Quality Control System: Target for Alzheimer's Disease Therapy.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Alzheimer's disease (AD) lacks effective early diagnostic tools. N-glycosylation dysregulation involving the enzyme MGAT3 is implicated in AD pathogenesis, with untapped clinical potential for biomarker development. Objective: To identify and validate MGAT3-associated diagnostic biomarkers for AD using integrative multi-disciplinary approaches. Methods: Bibliometric analysis of N-glycosylation-AD research; large-scale GEO dataset preprocessing, WGCNA-integrated bioinformatics, machine learning, and penalized regression in well-characterized independent training/validation sets. Results: Bibliometric analysis revealed -1.94% annual growth, 21.76% international co-authorship, leading contributions from the U.S., Japan, and China; Conclusions: MGAT3-associated biomarkers (ATP6V1G2, CHST6) and their combinations offer promising AD diagnostic potential, advancing insights into N-glycosylation-mediated disease mechanisms.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.